Systemic hypertension is a major global problem contributing to enormous disease burden,
premature morbidity and mortality. A substantial majority of hypertensive patients require …

Calcium channel blockers (CCBs), particularly dihydropyridine-CCBs,(DHP-CCBs), have an
established role in antihypertensive therapy, either as monotherapy or in combination with …

This review summarizes data on the effectiveness of lercanidipine. Lercanidipine is
dihydropyridine calcium antagonist of the third generation, characterized by high …

Objective: To review the literature regarding the efficacy, tolerability, and utility of
lercanidipine in the treatment of hypertension. Data Sources: A search of the literature was …

To determine whether the antihypertensive effectiveness of lercanidipine was independent
of the different cardiovascular risk levels. Patients with treated or untreated mild‐to …

Aim: Lercanidipine, a long-acting dihydropyridine with a good antihypertensive efficacy and
tolerability in clinical use. With the aim to determine the efficacy and tolerability of this drug in …

Lercanidipine has demonstrated a good antihypertensive efficacy and an excellent
tolerability profile, not only in randomized clinical trials but also in daily clinical practice. With …

The efficacy and tolerability of lercanidipine, a new dihydropyridine calcium antagonist, were
assessed in comparison with atenolol in a randomized, double-blind, multicenter trial in …

Lercanidipine (Zanidip®) is a vasoselective dihydropyridine calcium channel antagonist that
causes systemic vasodilation by blocking the influx of calcium ions through L-type calcium …

Lercanidipine is a vasoselective dihydropyridine calcium antagonist which causes systemic
vasodilation by blocking the influx of calcium ions through L-type calcium channels in cell …